Login / Signup

Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.

James YarmolinskyVirginia Díez-ObreroTom G RichardsonMarie PigeyreJennifer SjaardaGuillaume ParéVenexia M WalkerEmma E VincentVanessa Y TanMireia Obon-SantacanaDemetrius AlbanesJochen HampeAndrea GsurHeather HampelRish K PaiMark E JenkinsSteven GallingerGraham CaseyQuan LongChristopher Ian Amosnull nullnull nullnull nullGeorge Davey SmithRichard M MartinVictor Moreno
Published in: PLoS medicine (2022)
In this study, we observed that genetically proxied long-term ACE inhibition was associated with an increased risk of colorectal cancer, warranting comprehensive evaluation of the safety profiles of ACE inhibitors in clinical trials with adequate follow-up. There was little evidence to support associations across other drug target-cancer risk analyses, consistent with findings from short-term randomized controlled trials for these medications.
Keyphrases
  • clinical trial
  • randomized controlled trial
  • angiotensin converting enzyme
  • angiotensin ii
  • blood pressure
  • adverse drug
  • emergency department
  • systematic review
  • phase ii
  • young adults